Zobrazeno 1 - 10
of 96
pro vyhledávání: '"Indoles/administration '
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Kunevičius, Arnas1 (AUTHOR) arnas.kunevicius@gmc.vu.lt, Sadauskas, Mikas2 (AUTHOR) mikas.sadauskas@bchi.vu.lt, Raudytė, Julija1 (AUTHOR), Meškys, Rolandas2 (AUTHOR), Burokas, Aurelijus1 (AUTHOR) arnas.kunevicius@gmc.vu.lt
Publikováno v:
Molecules. Mar2024, Vol. 29 Issue 5, p993. 16p.
Publikováno v:
Biomedical Research. 5:473-480
Mitochondrial oxidative metabolism contributes to a cancer stem cell phenotype in cholangiocarcinoma
Autor:
Matteo Ramazzotti, Luca Viganò, Mirella Pastore, Maria Letizia Taddei, Monika Lewinska, Javier Cibella, Clelia Peano, Erica Pranzini, Luca Di Tommaso, Elena Sacco, Jessica Iorio, Paola Chiarugi, S. Madiai, Jesper B. Andersen, Chiara Raggi, Ivan Orlandi, B. Piombanti, Giovanni Di Maira, Margherita Correnti, N. Navari, Tiziano Lottini, Annarosa Arcangeli, Giulia Lori, Claudia Campani, Fabio Marra
Publikováno v:
Raggi, C, Taddei, M L, Sacco, E, Navari, N, Correnti, M, Piombanti, B, Pastore, M, Campani, C, Pranzini, E, Iorio, J, Lori, G, Lottini, T, Peano, C, Cibella, J, Lewinska, M, Andersen, J B, di Tommaso, L, Viganò, L, Di Maira, G, Madiai, S, Ramazzotti, M, Orlandi, I, Arcangeli, A, Chiarugi, P & Marra, F 2021, ' Mitochondrial oxidative metabolism contributes to a cancer stem cell phenotype in cholangiocarcinoma ', Journal of Hepatology, vol. 74, no. 6, pp. 1373-1385 . https://doi.org/10.1016/j.jhep.2020.12.031
BACKGROUND & AIMS: Little is known about the metabolic regulation of cancer stem cells (CSCs) in cholangiocarcinoma (CCA). We analyzed whether mitochondrial-dependent metabolism and related signaling pathways contribute to stemness in CCA.METHODS: Th
Autor:
Harry G M Heijerman, Edward F McKone, Damian G Downey, Eva Van Braeckel, Steven M Rowe, Elizabeth Tullis, Marcus A Mall, John J Welter, Bonnie W Ramsey, Charlotte M McKee, Gautham Marigowda, Samuel M Moskowitz, David Waltz, Patrick R Sosnay, Christopher Simard, Neil Ahluwalia, Fengjuan Xuan, Yaohua Zhang, Jennifer L Taylor-Cousar, Karen S McCoy, Karen McCoy, Scott Donaldson, Seth Walker, James Chmiel, Ronald Rubenstein, Deborah K. Froh, Isabel Neuringer, Manu Jain, Kathryn Moffett, Jennifer L. Taylor-Cousar, Bruce Barnett, Gary Mueller, Patrick Flume, Floyd Livingston, Nighat Mehdi, Charlotte Teneback, John Welter, Raksha Jain, Dana Kissner, Kapilkumar Patel, Francisco J. Calimano, Jimmy Johannes, Cori Daines, Thomas Keens, Herschel Scher, Subramanyam Chittivelu, Sudhakar Reddivalam, Ross Carl Klingsberg, Larry G. Johnson, Stijn Verhulst, Patricia Macedo, Damien Downey, Gary Connett, Edward Nash, Nicholas Withers, Timothy Lee, Marleen Bakker, Harry Heijerman, Francois Vermeulen, Christiane Knoop, Elke De Wachter, Renske van der Meer, Petrus Merkus, Christof Majoor
Publikováno v:
Lancet, 394(10212), 1940-1948. Elsevier Limited
VX17-445-103 Trial Group 2019, ' Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial ', Lancet, vol. 394, no. 10212, pp. 1940 . https://doi.org/10.1016/S0140-6736(19)32597-8
Lancet
The Lancet, 394(10212), 1940. Elsevier Limited
VX17-445-103 Trial Group 2019, ' Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial ', Lancet, vol. 394, no. 10212, pp. 1940 . https://doi.org/10.1016/S0140-6736(19)32597-8
Lancet
The Lancet, 394(10212), 1940. Elsevier Limited
BACKGROUND: Cystic fibrosis transmembrane conductance regulator (CFTR) modulators correct the basic defect caused by CFTR mutations. Improvements in health outcomes have been achieved with the combination of a CFTR corrector and potentiator in people
Autor:
Daniel Peckham, Paul Whitaker, Anil Mehta, Sinisa Savic, Michael F. McDermott, T. Scambler, J. Holbrook, Christine Etherington, Ian Clifton, Heledd H. Jarosz-Griffiths, Samuel Lara-Reyna, Giulia Spoletini, C. Wong, Fabio Martinon
Publikováno v:
eLife
eLife, Vol 9 (2020)
eLife, vol. 9, pp. e54556
eLife, Vol 9 (2020)
eLife, vol. 9, pp. e54556
Previously, we showed that serum and monocytes from patients with CF exhibit an enhanced NLRP3-inflammasome signature with increased IL-18, IL-1β, caspase-1 activity and ASC speck release (Scambler et al. eLife 2019). Here we show that CFTR modulato
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e56c3b19820b0ec649de1acb486b5ee6
https://eprints.whiterose.ac.uk/158253/7/elife-54556-v2.pdf
https://eprints.whiterose.ac.uk/158253/7/elife-54556-v2.pdf
Autor:
Anna Geraths, Stefan W. Toennes, Werner Pogoda, Alexander Paulke, Johannes G. Ramaekers, Eef L. Theunissen, Cora Wunder
Publikováno v:
Drug Testing and Analysis, 10(4), 644-650. John Wiley & Sons Inc.
Each year, synthetic cannabinoids occur in high numbers on the illicit drug market, but data on their detectability are rarely available. A pilot study was performed to assess adverse effects of JWH-018, which is one of the oldest and best known synt
Autor:
Werner Pogoda, Alexander Paulke, Stefan W. Toennes, Johannes G. Ramaekers, Anna Geraths, Eef L. Theunissen, Cora Wunder
Publikováno v:
Journal of Pharmaceutical and Biomedical Analysis, 150, 162-168. Elsevier
Each year, synthetic cannabinoids are occurring in high numbers on the illicit drug market but data obtained after controlled application are rare. The present study on pharmacokinetics in urine is part of a pilot study on adverse effects of JWH-018,
Publikováno v:
British Journal of Pharmacology. 175(1):18-28
BACKGROUND AND PURPOSE: Synthetic cannabinoids (often sold as Spice or K2) have become a very popular alternative to cannabis due to their easy access and portrayed safety. Controlled studies on the behavioural effects of synthetic cannabinoids are c
Autor:
VX17-445-103 Trial Group
Background: Cystic fibrosis transmembrane conductance regulator (CFTR) modulators correct the basic defect caused by CFTR mutations. Improvements in health outcomes have been achieved with the combination of a CFTR corrector and potentiator in people
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_____10691::89138b60eee52c990cd8474204258594
https://dspace.library.uu.nl/handle/1874/391989
https://dspace.library.uu.nl/handle/1874/391989